

December 2, 2019

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director,

President and Chief Executive Officer

**Monthly Exercise Status of the 47<sup>th</sup> Stock Acquisition Rights (with Exercise Price Revision Clauses)  
Issued by way of Third Party Allotment**

TOKYO, Japan, December 2, 2019- The monthly exercise status for November of 47<sup>th</sup> Stock Acquisition Rights issued and allotted to EVO FUND on April 25, 2018.

(1)	Name of stock acquisition rights	SymBio Pharmaceuticals Limited 47 <sup>th</sup> Stock Acquisition Rights
(2)	Number of shares delivered for the month	950,000 Shares
(3)	Number of stock acquisition rights exercised during the month and exercise ratio to the total number of stock acquisition rights issued	3,800,000 Units (Ratio to total 15,000,000 Units Issued : 25.3 %)
(4)	Number of unexercised stock acquisition rights at the end of the previous month	15,000,000 Units
(5)	Number of unexercised stock acquisition rights at the end of the month	11,200,000 Units

(6) Exercise Status for respective month

Exercise Date	Number of shares issued		Exercise Price (¥)	Number of stock acquisition rights exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
November 14(Mon) to November 20 (Wed)	—	—	665	—
November 21 (Thu)	—	—	609	—
November 22 (Fri)	200,000	—	609	800,000
November 25 (Mon)	200,000	—	609	800,000
November 26 (Tue)	—	—	609	—
November 27 (Wed)	450,000	—	609	1,800,000
November 28 (Thu)	100,000	—	621	400,000
November 29 (Fri)	—	—	621	—

※Number of issued shares at the end of the previous month : 24,3362,681 shares [of which 11,068 shares are treasury shares]

※※Exercise status is reported from the exercise start date (November 14, 2019)

(7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)

① Total number of shares to be delivered upon the exercise of all series of stock acquisition rights	② Number of listed shares at the time of the payment for the issuance	③ Exercise ratio on exercise limit (①/②)
950,000 Shares	14,460,181 Shares	6.57%

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.